TheStreet
JIM CRAMERINVESTINGPERSONAL FINANCERETIREMENTTECHNOLOGYMARKETSHOW-TOVIDEOFINANCIAL ADVISOR CENTER
Search

LATEST NEWS

Heat Biologics Takes Beating After Pricing $12 Million Stock Offering
INVESTING

Heat Biologics Takes Beating After Pricing $12 Million Stock Offering

PRESS RELEASES

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRESS RELEASES

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRESS RELEASES

Akebia Therapeutics To Present At 39th Annual J.P. Morgan Healthcare Conference

PRESS RELEASES

AkebiaShares Program: Current Approaches For Managing Hyperphosphatemia And Caring For Patients Via Telehealth

PRESS RELEASES

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRESS RELEASES

Akebia Therapeutics To Participate In Piper Sandler 32nd Annual Virtual Healthcare Conference

PRESS RELEASES

Akebia Therapeutics Ranked 10th Fastest-Growing Company In North America On Deloitte's 2020 Technology Fast 500™

PRESS RELEASES

Akebia Announces Manuscript Highlighting Global Phase 3 INNO2VATE Program Rationale, Study Design And Baseline Characteristics Published In Peer-Reviewed Medical Journal

PRESS RELEASES

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRESS RELEASES

Akebia Therapeutics To Report Third Quarter 2020 Financial Results And Discuss Recent Business Highlights

PRESS RELEASES

Akebia Presents Results From Its INNO2VATE Global Phase 3 Program; Demonstrated Efficacy And Cardiovascular Safety Of Vadadustat For The Treatment Of Anemia Due To Chronic Kidney Disease In Adult Patients On Dialysis

PRESS RELEASES

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRESS RELEASES

Akebia Therapeutics Announces September 2020 Investor Conference Schedule

PRESS RELEASES

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRESS RELEASES

Akebia Therapeutics Announces First Commercial Launch Of VAFSEO™ (vadadustat Tablets), A New Oral Treatment For Anemia Due To Chronic Kidney Disease, In Japan

PRESS RELEASES

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRESS RELEASES

Akebia Therapeutics Announces Approval Of Vadadustat In Japan For The Treatment Of Anemia Due To Chronic Kidney Disease In Dialysis-Dependent And Non-Dialysis Dependent Adult Patients

PRESS RELEASES

Akebia Therapeutics Launches AkebiaShares, A Peer-to-Peer Educational Program Series For The Renal Community

PRESS RELEASES

Akebia Therapeutics Announces New Chief Financial Officer

PRESS RELEASES

Akebia Therapeutics Announces Data On Different Dosing Regimens Of Ferric Citrate For Iron Deficiency Anemia Presented At 57th ERA-EDTA Virtual Congress

PRESS RELEASES

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRESS RELEASES

Akebia Therapeutics To Present At Jefferies Virtual Global Healthcare Conference

PRESS RELEASES

Akebia Therapeutics Announces Change To Virtual Annual Meeting Of Stockholders

PRESS RELEASES

Akebia Therapeutics Announces Full Exercise Of Underwriters' Option To Purchase Additional Shares